Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stada Arzneimittel AG

www.stada.de

Latest From Stada Arzneimittel AG

2017's Top Biopharma Deal-makers

A co-development and co-commercialization agreement between AstraZeneca and Merck, one of the largest of 2017, continued the dominance of immuno-oncology in partnerships. There was significant consolidation in the consumer health industry, coupled with CVS and Aetna's major move to change health care delivery.

Deals Market Intelligence

Five Biologic Blockbusters Opened Up To EU Biosimilar Competition In 2017

A total of 16 biosimilar products were approved in 2017, including the first competitors to five biologic blockbusters. Coincidentally, 16 other biosimilars are also under evaluation by the European Medicines Agency’s main scientific committee, the CHMP, including six versions of Amgen’s Neulasta (pegfilgrastim) and five more biosimilars of AbbVie’s Humira.

Biosimilars Approvals

Cardinal China Sell-Off Deal Advances

The potential acquisition of Cardinal Health’s China business by Shanghai Pharmaceuticals could have significant strategic implications for the state-owned suitor, but it’s probably still “hard to assume” how the transaction may finally pan out. Expectations around the deal value are still in excess of $1bn, investor sources tell Scrip.

BioPharmaceutical China

Quarterly Reporting: Investor Reality Check Or Pharma Communication Gap?

Multi-billion dollar gaps exist between what investors think a company is worth one day and what they think the next. A Scrip analysis shows that these information gaps between big pharma and their shareholders are very common and are often bridged only by the mandatory quarterly reporting from companies. While unbalanced optimism or pessimism from investors might account for some of the chasm in understanding, an absence of interim guidance from companies is also a factor.

Leadership Companies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register